LACY JERNIGAN: Open Payments
NPI 1306998174 · OCALA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$338 in 14 payments from 10 companies in 2025. Trend: 2023 $578 · 2024 $425 · 2025 $338
Food & beverage: $338
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $85 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| UCB, Inc. | 2 | $39 |
| ARGENX US, INC. | 1 | $32 |
| Celgene Corporation | 1 | $30 |
| Grifols USA, LLC | 1 | $27 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Life Molecular Imaging Ltd | 1 | $20 |
| Novartis Pharmaceuticals Corporation | 1 | $17 |
| Eisai Inc. | 1 | $15 |
Products named: QULIPTA, AUSTEDO XR, VYVGART HYTRULO, ZEPOSIA, UBRELVY, Gamunex-C, INGREZZA, Briviact.
Industry payments across FL — which companies pay providers there.
